Home  |  Contact

Cellosaurus SMS-KCNR (CVCL_7134)

[Text version]

Cell line name SMS-KCNR
Accession CVCL_7134
Resource Identification Initiative To cite this cell line use: SMS-KCNR (RRID:CVCL_7134)
Comments Doubling time: ~72 hours (PubMed=3456456).
Omics: Array-based CGH.
Omics: Transcriptome analysis.
Sequence variations
  • Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18923523).
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Derived from metastatic site: Bone marrow.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_AQ28 ! SMS-KCL
Sex of cell Male
Age at sampling 11M
Category Cancer cell line
STR profile Source(s): COG


Run an STR similarity search on this cell line
Web pages http://www.cccells.org/dl/NB_Data_Sheets/SMS-KCNR_Cell_Line_Data_Sheet_COGcell_org.pdf

Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.
Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Cancer Res. 42:1331-1336(1982)

PubMed=3456456; DOI=10.1093/jnci/76.3.375
Reynolds C.P., Biedler J.L., Spengler B.A., Reynolds D.A., Ross R.A., Frenkel E.P., Smith R.G.
Characterization of human neuroblastoma cell lines established before and after therapy.
J. Natl. Cancer Inst. 76:375-387(1986)

Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)

PubMed=8665486; DOI=10.1016/0304-3835(96)04250-4
Diccianni M.B., Chau L.S., Batova A., Vu T.Q., Yu A.L.-T.
The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
Cancer Lett. 104:183-192(1996)

PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7
Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R., De Paepe A., Cremer T., Speleman F.
Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
Cancer Genet. Cytogenet. 97:135-142(1997)

Thiele C.J.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)

PubMed=15390183; DOI=10.1002/gcc.20096
Gebauer S., Yu A.L.-T., Omura-Minamisawa M., Batova A., Diccianni M.B.
Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Genes Chromosomes Cancer 41:297-308(2004)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=18923523; DOI=10.1038/nature07398
Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O.
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Nature 455:967-970(2008)

PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

Cell line databases/resources CGH-DB; 9100-4
Encyclopedic resources Wikidata; Q54954992
Gene expression databases GEO; GSM692866
Polymorphism and mutation databases Cosmic; 848941
Cosmic; 922673
Cosmic; 1019950
Cosmic; 1109112
Cosmic; 1153804
Cosmic; 1167413
Cosmic; 1518067
Cosmic; 1526651
Cosmic; 2239460
Cosmic; 2393633
Entry history
Entry creation04-Apr-2012
Last entry update23-Jun-2022
Version number21